echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Luye Pharma's innovative drug Liss' Mingdo Day transdermal patch obtained EU multi-country marketing authorization qualification

    Luye Pharma's innovative drug Liss' Mingdo Day transdermal patch obtained EU multi-country marketing authorization qualification

    • Last Update: 2021-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Luye Pharmaceutical Group announced that its self-developed innovative preparation, Liss’ Mindo Day transdermal patch, has successfully passed the EU decentralized review process.


    Alzheimer's disease is an irreversible neurodegenerative disease.


    Alzheimer's disease is known as one of the most difficult treatment areas to break through.


    Outside of the European market, Liss's Mingda day transdermal patch is about to start phase III clinical trials in Japan.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.